Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 7/20 | 0.69 |
| ▸ | CASR | P41180 | 12/20 | 0.67 |
| ▸ | ADRB2 | P07550 | 9/20 | 0.64 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.64 |
| ▸ | ADRB3 | P13945 | 6/20 | 0.64 |
| ▸ | ADRB1 | P08588 | 4/20 | 0.64 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.64 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.64 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.64 |
| ▸ | HTR2B | P41595 | 3/20 | 0.64 |
| ▸ | NR2E1 | Q9Y466 | 3/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.64 |
| ▸ | HTR2A | P28223 | 3/20 | 0.64 |
| ▸ | HTR2C | P28335 | 3/20 | 0.64 |
| ▸ | HTR6 | P50406 | 3/20 | 0.64 |
| ▸ | SCN1A | P35498 | 2/20 | 0.64 |
| ▸ | SLC10A1 | Q14973 | 2/20 | 0.64 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.64 |
| ▸ | SCN3A | Q9NY46 | 2/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11143271 | 0.92 | CYP2D6 (0.65) | CYP2D6CASRADRB2SLC6A4ADRB3 | |
| SCHEMBL11137275 | 0.92 | CYP2D6 (0.65) | CYP2D6CASRADRB2SLC6A4ADRB3 | |
| SCHEMBL14382940 | 0.92 | CYP2D6 (0.65) | CYP2D6CASRADRB2SLC6A4ADRB3 | |
| SCHEMBL11137311 | 0.92 | CYP2D6 (0.65) | CYP2D6CASRADRB2SLC6A4ADRB3 | |
| Hydrochloric Acid SCHEMBL5517357 | 0.91 | CYP2D6 (0.64) | CYP2D6CASRADRB2SLC6A4ADRB3 | |
| SCHEMBL11137529 | 0.90 | CASR (0.78) | CYP2D6CASRADRB2SLC6A4ADRB3 | |
| SCHEMBL14383089 | 0.90 | CASR (0.78) | CYP2D6CASRADRB2SLC6A4ADRB3 | |
| SCHEMBL14383090 | 0.90 | CASR (0.78) | CYP2D6CASRADRB2SLC6A4ADRB3 | |
| Hydrochloric Acid SCHEMBL5517095 | 0.89 | CASR (0.77) | CYP2D6CASRADRB2SLC6A4ADRB3 | |
| Hydrochloric Acid SCHEMBL5518953 | 0.89 | CASR (0.77) | CYP2D6CASRADRB2SLC6A4ADRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070249702-A1 | CALCILYTIC COMPOUNDS | GLAXOSMITHKLINE LLC | 2007-10-25 | — | — | US | disclosed |
| US-7202261-B2 | Calcilytic compounds | NPS PHARMACEUTICALS, INC. (US) | 2007-04-10 | — | — | US | disclosed |
| EP-0901459-B1 | CALCILYTIC COMPOUNDS | NPS PHARMA INC (US) | 2005-06-29 | — | — | EP | disclosed |
| US-20050032850-A1 | Calcilytic compounds | NPS PHARMACEUTICALS, INC. | 2005-02-10 | — | — | US | disclosed |
| US-6818660-B2 | FOR INHIBITING CALCIUM RECEPTOR ACTIVIT; TO STIMULATE SECRETION OF PARATHYROID HORMONE (PTH); FOR BONE FORMATION | NPS PHARMACEUTICALS, INC. | 2004-11-16 | — | — | US | disclosed |
| US-6521667-B1 | Calcilytic compounds | NPS PHARMACEUTICALS, INC. | 2003-02-18 | — | — | US | disclosed |
| US-6432656-B1 | Calcilytic compounds | NPS PHARMACEUTICALS, INC. | 2002-08-13 | — | — | US | disclosed |
| US-20020099220-A1 | Calcilytic compounds | NPS PHARMACEUTICALS, INC. | 2002-07-25 | — | — | US | disclosed |
| US-6022894-A | Method of using calcilytic compounds | NPS PHARMACEUTICALS, INC. (US) | 2000-02-08 | — | — | US | disclosed |
| EP-0901459-A1 | CALCILYTIC COMPOUNDS | NPS PHARMACEUTICALS, INC. (US) | 1999-03-17 | — | — | EP | disclosed |
| WO-1997037967-A1 | CALCILYTIC COMPOUNDS | NPS PHARMACEUTICALS, INC. (US) | 1997-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032850-A1 | Calcilytic compounds | CALCR, CASR, ORAI1 | CYP2D6 4067/4885CASR 2/4885ADRB2 482/4885 |
| US-20070249702-A1 | CALCILYTIC COMPOUNDS | CALCR, CASR, ORAI1 | CYP2D6 4067/4885CASR 2/4885ADRB2 482/4885 |
| US-20020099220-A1 | Calcilytic compounds | CALCR, CASR, CALCRL | CYP2D6 3907/4885CASR 2/4885ADRB2 701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.